Pentixapharm Restructures Operations with 50% Workforce Reduction to Focus on Advanced Clinical Programs
Pentixapharm Holding AG is implementing significant organizational changes including a 50% workforce reduction and reduced early-stage research to concentrate resources on its most advanced clinical development programs, particularly the Phase 3-ready CXCR4 program for treatment-resistant hypertension diagnosis.
The Managing Board and Supervisory Board of Pentixapharm Holding AG have resolved to significantly reduce early-stage research and development activities while concentrating resources on the company's most advanced clinical programs. This strategic prioritization allows the advanced clinical-stage biotech company to invest more effectively in its most value-generating development programs, including the Phase 3-ready CXCR4 flagship program for improved diagnosis of treatment-resistant hypertension.
The organizational restructuring includes a targeted workforce reduction of approximately 50% at Pentixapharm AG, with implementation expected to be completed in the first quarter of 2026. These measures are anticipated to lower annual operating costs and extend the company's cash runway through the first quarter of 2027. The decision represents a continuation of the clinical development strategy introduced in May 2025, which prioritizes high-value CXCR4-targeted programs.
Dr. Dirk Pleimes, CEO and CMO of Pentixapharm AG, emphasized the strategic importance of these changes, stating that the Phase 3-ready PentixaFor CXCR4 program for diagnosing treatment-resistant hypertension has made significant progress and remains a central value driver. The optimization of operational costs is designed to enhance company efficiency and establish a solid foundation for achieving upcoming clinical milestones. The company plans to implement these measures responsibly while supporting affected employees throughout the transition period.
Pentixapharm's clinical pipeline focuses on CXCR4-targeted PET-CT programs, including the advanced candidate for improved diagnosis of hypertensive patients with primary aldosteronism. This program aims to enable targeted treatment of underlying hypertension causes. The company's development portfolio also includes CXCR4-based therapeutic programs in hematological cancers and a next-generation antibody platform targeting CD24, an emerging immune-checkpoint marker over-expressed in multiple hard-to-treat cancers. Additional information about the company's developments can be found at https://www.newmediawire.com.